Pembrolizumab (Keytruda)

Combination TherapyApproved for: NSCLCPD-L1 Pembrolizumab (Keytruda) approved Combination Therapy for non-small cell lung cancer (NSCLC) with the biomarker PD-L1. It is used: Alone as first-line treatment in patients whose cancer has the PD-L1 protein and does not have a...
|
May 30, 2021
|

Atezolizumab (Tecentriq)

Targeted TherapyApproved for: NSCLCBiomarker: PD-L1 Atezolizumab (Tecentriq) is a FDA-approved treatment for non-small cell lung cancer that has metastasized. It is used: As first-line therapy in adults whose cancer has the PD-L1 protein and does not have a mutation...
|
May 27, 2021
|

Nivolumab (Opdivo/Opdivo Injection)

Targeted TherapyApproved for: NSCLCBiomarker: PD-L1 Nivolumab (Opdivo/Opdivo Injection) is an FDA-approved treatment for non-small cell lung cancer (NSCLC). It is used: As first-line therapy with ipilimumab in adults whose cancer is metastatic and has the PD-L1 protein but does...
|
May 27, 2021
|